Dapagliflozin Efficacy & Safety as Mono or Combination therapy in reduction of HbA1C and Body Weight in Type II Diabetes Mellitus Patients. - Trial IRCT20170614034526N5
Access comprehensive clinical trial information for IRCT20170614034526N5 through Pure Global AI's free database. This phase not specified trial is sponsored by Hilton Pharma Pvt Ltd and is currently Completed. The study focuses on Type 2 Diabetes mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Iranian Registry Of Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
IRCT20170614034526N5
Completed
drug
Trial Details
Iranian Registry Of Clinical Trial • IRCT20170614034526N5
Dapagliflozin Efficacy & Safety as Mono or Combination therapy in reduction of HbA1C and Body Weight in Type II Diabetes Mellitus Patients.
Prospective Efficacy & Safety study of Monotherapy or Combination therapy with Dapagliflozin in reduction of HbA1C and Body Weight in newly diagnosed or treatment experienced Type II Diabetes Mellitus Patients.
Study Focus
Sponsor & Location
Hilton Pharma Pvt Ltd
Pakistan
Timeline & Enrollment
N/A
Dec 03, 2018
N/A
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
Iranian Registry Of Clinical Trial
IRCT20170614034526N5
Non-Device Trial